Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CATHY B BARNES

Allopathic & Osteopathic Physicians Family Medicine

NPI
1821089756
CMS profile
309044
Location
TRINITY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$2,414.87

43 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,786.98 9
Food and Beverage $627.89 34

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $2,352.21 42
Janssen Pharmaceuticals, Inc $62.66 1

Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CATHY B BARNES

NPI 1821089756 · CMS profile ID 309044

Allopathic & Osteopathic Physicians / Family Medicine

TRINITY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1821089756?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CATHY B BARNES, NPI 1821089756, CMS profile ID 309044. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1821089756?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). CATHY B BARNES, NPI 1821089756, CMS profile ID 309044. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1821089756?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
CATHY B BARNES, NPI 1821089756, CMS profile ID 309044, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1821089756?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

43 matching records · $2,414.87 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 43 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–43 of 43.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $41.1003/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728357795 CMS
Eli Lilly and Company $95.6303/24/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728381709 CMS
Eli Lilly and Company $2.9903/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728357799 CMS
Eli Lilly and Company $61.7503/05/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728357801 CMS
Eli Lilly and Company $83.3003/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728361219 CMS
Eli Lilly and Company $0.9503/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728361221 CMS
Eli Lilly and Company $4.8603/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728361223 CMS
Eli Lilly and Company $44.2003/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728361225 CMS
Eli Lilly and Company $13.6003/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728364665 CMS
Eli Lilly and Company $5.9503/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728364667 CMS
Eli Lilly and Company $20.8303/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728368115 CMS
Eli Lilly and Company $1.0403/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728368117 CMS
Eli Lilly and Company $13.0003/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728371577 CMS
Eli Lilly and Company $9.1603/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728374935 CMS
Eli Lilly and Company $2.9903/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728374937 CMS
Eli Lilly and Company $23.8003/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728378509 CMS
Eli Lilly and Company $11.0503/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728378511 CMS
Eli Lilly and Company $1.9003/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728381711 CMS
Eli Lilly and Company $248.0003/05/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753917065 CMS
Eli Lilly and Company $606.6003/04/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728357793 CMS
Eli Lilly and Company $23.3803/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728357797 CMS
Eli Lilly and Company $1.9003/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728361217 CMS
Eli Lilly and Company $4.6803/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728364661 CMS
Eli Lilly and Company $7.9603/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728364663 CMS
Eli Lilly and Company $0.9803/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728368111 CMS
Eli Lilly and Company $2.9803/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728368113 CMS
Eli Lilly and Company $240.0003/03/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728371565 CMS
Eli Lilly and Company $10.2903/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728371567 CMS
Eli Lilly and Company $93.5003/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728371569 CMS
Eli Lilly and Company $4.8603/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728371571 CMS
Eli Lilly and Company $0.9503/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728371573 CMS
Eli Lilly and Company $2.9803/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728371575 CMS
Eli Lilly and Company $157.0003/03/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728374933 CMS
Eli Lilly and Company $23.8003/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728378501 CMS
Eli Lilly and Company $5.9503/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728378503 CMS
Eli Lilly and Company $11.9003/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728378505 CMS
Eli Lilly and Company $65.0003/03/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728378507 CMS
Eli Lilly and Company $33.1503/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728381701 CMS
Eli Lilly and Company $44.2003/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728381703 CMS
Eli Lilly and Company $11.0503/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728381705 CMS
Eli Lilly and Company $65.0003/03/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728381707 CMS
Eli Lilly and Company $248.0003/03/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753916543 CMS
Janssen Pharmaceuticals, Inc $62.6602/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719071873 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $242.96 3
PY2020 $2,414.87 43
PY2021 $102.51 1
PY2022 $81.28 1
PY2024 $1,292.30 10
PY2025 $1,335.09 13

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,205,743.80 119
PY2024 Recipient $34,906.00 2
PY2024 Principal investigator $2,451,942.71 49
PY2023 Recipient $2,790.56 3
PY2023 Principal investigator $2,713,362.43 33
PY2022 Recipient $28,555.00 4
PY2022 Principal investigator $1,298,287.06 112
PY2021 Principal investigator $858,224.34 839
PY2020 Recipient $142.50 1
PY2020 Principal investigator $353,224.47 119
PY2019 Recipient $12,826.75 13
PY2019 Principal investigator $389,491.61 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $219.71 12/31/2019 Non-covered Recipient Entity
Suncoast Clinical Research
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 684992239
Principal investigator 1 AstraZeneca UK Limited $870.00 12/31/2019 Non-covered Recipient Entity
Suncoast Clinical Research
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 685001519
Principal investigator 1 AbbVie, Inc. $9,800.00 11/26/2019 Non-covered Recipient Entity
Suncoast Clinical Research
M15-999 No dispute reported 06/30/2026 647591925
Principal investigator 1 SANOFI US SERVICES INC. $3,113.00 11/25/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 691599022
Principal investigator 1 AbbVie, Inc. $11,821.90 11/21/2019 Non-covered Recipient Entity
Suncoast Clinical Research
M15-999 No dispute reported 06/30/2026 647591927
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,384.20 11/21/2019 Non-covered Recipient Entity
Suncoast Clinical Research
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 684992227
Principal investigator 1 SANOFI US SERVICES INC. $2,520.00 11/18/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine No dispute reported 06/30/2026 691598995
Principal investigator 1 Akcea Therapeutics, Inc. $11,524.50 11/13/2019 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH INC
ISIS 678354-CS2 No dispute reported 06/30/2026 703181347
Principal investigator 1 SANOFI US SERVICES INC. $1,776.00 10/28/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 691595949
Principal investigator 1 SANOFI US SERVICES INC. $3,129.00 10/28/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine No dispute reported 06/30/2026 691596137
Principal investigator 1 AbbVie, Inc. $2,100.40 10/21/2019 Non-covered Recipient Entity
Suncoast Clinical Research
M15-999 No dispute reported 06/30/2026 647591923
Principal investigator 1 SANOFI US SERVICES INC. $10,100.00 10/17/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 691607849
Principal investigator 1 SANOFI US SERVICES INC. $11,372.00 10/15/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine No dispute reported 06/30/2026 691594809
Principal investigator 1 Akcea Therapeutics, Inc. $4,317.00 10/10/2019 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH INC
ISIS 678354-CS2 No dispute reported 06/30/2026 703181238
Principal investigator 1 Akcea Therapeutics, Inc. $1,156.00 10/10/2019 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH INC
ISIS 678354-CS2 No dispute reported 06/30/2026 703181241
Principal investigator 1 Akcea Therapeutics, Inc. $9,287.00 10/10/2019 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH INC
ISIS 678354-CS2 No dispute reported 06/30/2026 703181245
Principal investigator 1 SANOFI US SERVICES INC. $2,450.00 10/02/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 691588177
Principal investigator 1 AbbVie, Inc. $2,987.00 09/19/2019 Non-covered Recipient Entity
Suncoast Clinical Research
M15-999 No dispute reported 06/30/2026 647591921
Principal investigator 1 Akcea Therapeutics, Inc. $741.00 09/11/2019 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH INC
ISIS 678354-CS2 No dispute reported 06/30/2026 703181023
Principal investigator 1 AbbVie, Inc. $1,862.50 09/04/2019 Non-covered Recipient Entity
Suncoast Clinical Research
M15-999 No dispute reported 06/30/2026 647591919
Principal investigator 1 SANOFI US SERVICES INC. $6,323.00 08/26/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 691587397
Principal investigator 1 SANOFI US SERVICES INC. $1,554.00 07/29/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 691582797
Principal investigator 1 SANOFI US SERVICES INC. $2,375.00 07/29/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine No dispute reported 06/30/2026 691584675
Principal investigator 1 Akcea Therapeutics, Inc. $31,868.20 07/11/2019 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH INC
ISIS 678354-CS2 No dispute reported 06/30/2026 703180451
Principal investigator 1 SANOFI US SERVICES INC. $5,470.00 07/08/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 691585289
Principal investigator 1 SANOFI US SERVICES INC. $3,420.00 07/08/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 691594231
Principal investigator 1 Akcea Therapeutics, Inc. $16,975.40 07/04/2019 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH INC
ISIS 678354-CS2 No dispute reported 06/30/2026 703180241
Principal investigator 1 SANOFI US SERVICES INC. $4,645.00 07/02/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine No dispute reported 06/30/2026 691582093
Principal investigator 1 SANOFI US SERVICES INC. $2,707.00 06/10/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 691582678
Principal investigator 1 SANOFI US SERVICES INC. $8,531.00 06/10/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine No dispute reported 06/30/2026 691583431
Principal investigator 1 SANOFI US SERVICES INC. $7,289.00 05/29/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine No dispute reported 06/30/2026 691605277
Principal investigator 1 SANOFI US SERVICES INC. $6,200.00 05/20/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 691555243
Principal investigator 1 SANOFI US SERVICES INC. $1,059.00 04/22/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular No dispute reported 06/30/2026 691578969
Principal investigator 1 SANOFI US SERVICES INC. $17,321.00 04/08/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular No dispute reported 06/30/2026 691580633
Recipient SANOFI US SERVICES INC. $10.99 03/25/2019 Covered Recipient Physician Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog? Versus Continuous Use of NovoLog in Participants With Type No dispute reported 06/30/2026 691553513
Recipient SANOFI US SERVICES INC. $16.63 03/25/2019 Covered Recipient Physician Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog? Versus Continuous Use of NovoLog in Participants With Type No dispute reported 06/30/2026 691553517
Recipient SANOFI US SERVICES INC. $36.00 03/25/2019 Covered Recipient Physician Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog? Versus Continuous Use of NovoLog in Participants With Type No dispute reported 06/30/2026 691553519
Recipient SANOFI US SERVICES INC. $30.01 03/23/2019 Covered Recipient Physician Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog? Versus Continuous Use of NovoLog in Participants With Type No dispute reported 06/30/2026 691553279
Recipient SANOFI US SERVICES INC. $51.22 03/23/2019 Covered Recipient Physician Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog? Versus Continuous Use of NovoLog in Participants With Type No dispute reported 06/30/2026 691553285
Recipient SANOFI US SERVICES INC. $59.80 03/23/2019 Covered Recipient Physician Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog? Versus Continuous Use of NovoLog in Participants With Type No dispute reported 06/30/2026 691553289
Recipient SANOFI US SERVICES INC. $100.01 03/22/2019 Covered Recipient Physician Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog? Versus Continuous Use of NovoLog in Participants With Type No dispute reported 06/30/2026 691552171
Recipient SANOFI US SERVICES INC. $172.51 03/22/2019 Covered Recipient Physician Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog? Versus Continuous Use of NovoLog in Participants With Type No dispute reported 06/30/2026 691552175
Recipient SANOFI US SERVICES INC. $194.27 03/22/2019 Covered Recipient Physician Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog? Versus Continuous Use of NovoLog in Participants With Type No dispute reported 06/30/2026 691552181
Recipient SANOFI US SERVICES INC. $350.68 03/22/2019 Covered Recipient Physician Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog? Versus Continuous Use of NovoLog in Participants With Type No dispute reported 06/30/2026 691552187
Recipient SANOFI US SERVICES INC. $16.63 03/21/2019 Covered Recipient Physician Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog? Versus Continuous Use of NovoLog in Participants With Type No dispute reported 06/30/2026 691553841
Recipient SANOFI US SERVICES INC. $36.00 03/21/2019 Covered Recipient Physician Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog? Versus Continuous Use of NovoLog in Participants With Type No dispute reported 06/30/2026 691553847
Recipient Eli Lilly and Company $11,752.00 02/26/2019 Covered Recipient Physician A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654281501
Principal investigator 1 Eli Lilly and Company $36.70 02/20/2019 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654297597
Principal investigator 1 AstraZeneca UK Limited $5,481.00 02/19/2019 Non-covered Recipient Entity
Suncoast Clinical Research
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 685001513
Principal investigator 1 SANOFI US SERVICES INC. $10,807.00 02/11/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 691547767
Principal investigator 1 Eli Lilly and Company $142,318.00 01/29/2019 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654296367
Principal investigator 1 Eli Lilly and Company $711.60 01/28/2019 Non-covered Recipient Entity
RAINIER CLINICAL RESEARCH CENTER INC
A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654290379
Principal investigator 1 AstraZeneca UK Limited $3,207.50 01/22/2019 Non-covered Recipient Entity
Suncoast Clinical Research
ICON Project agreement Ireland scout phase 3 full service clinical trial outsourcing Saxa and Dapa vs Su bms CV181 36 No dispute reported 06/30/2026 685001515
Principal investigator 1 SANOFI US SERVICES INC. $18,661.00 01/21/2019 Non-covered Recipient Entity
Suncoast Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular No dispute reported 06/30/2026 691572965